Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Gastrointestinal 11Lymphoid 5Thoracic 4Other hematologic neoplasm 4Gynecologic 4Tumor-Agnostic 3Head & Neck 3Genitourinary 3Dermatologic 3Sarcoma 2Other solid neoplasm 2CNS 2NET 1Myeloid 1Endocrine 1

Conditions

Salivary Gland Neoplasms 1Recurrent Squamous Cell Carcinoma of the Nasopharynx 1Nasopharyngeal Carcinoma 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × MK 2206 × Head & Neck × Clear all
NCT01604772 2019-05-01

Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma

National Cancer Institute (NCI)

Phase 2 Completed
16 enrolled 7 charts
Head & Neck

Salivary Gland Neoplasms

NCT01349933 2017-12-05

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 11 charts
Head & Neck

Recurrent Squamous Cell Carcinoma of the Nasopharynx

NCT01370070 2017-01-13

MC1079

Chinese University of Hong Kong

Phase 2 Completed
12 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡